Arsenic Exposure, Blood DNA Methylation, and Cardiovascular Disease
- PMID: 35658476
- PMCID: PMC10203287
- DOI: 10.1161/CIRCRESAHA.122.320991
Arsenic Exposure, Blood DNA Methylation, and Cardiovascular Disease
Abstract
Background: Epigenetic dysregulation has been proposed as a key mechanism for arsenic-related cardiovascular disease (CVD). We evaluated differentially methylated positions (DMPs) as potential mediators on the association between arsenic and CVD.
Methods: Blood DNA methylation was measured in 2321 participants (mean age 56.2, 58.6% women) of the Strong Heart Study, a prospective cohort of American Indians. Urinary arsenic species were measured using high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry. We identified DMPs that are potential mediators between arsenic and CVD. In a cross-species analysis, we compared those DMPs with differential liver DNA methylation following early-life arsenic exposure in the apoE knockout (apoE-/-) mouse model of atherosclerosis.
Results: A total of 20 and 13 DMPs were potential mediators for CVD incidence and mortality, respectively, several of them annotated to genes related to diabetes. Eleven of these DMPs were similarly associated with incident CVD in 3 diverse prospective cohorts (Framingham Heart Study, Women's Health Initiative, and Multi-Ethnic Study of Atherosclerosis). In the mouse model, differentially methylated regions in 20 of those genes and DMPs in 10 genes were associated with arsenic.
Conclusions: Differential DNA methylation might be part of the biological link between arsenic and CVD. The gene functions suggest that diabetes might represent a relevant mechanism for arsenic-related cardiovascular risk in populations with a high burden of diabetes.
Keywords: DNA methylation; arsenic; cardiovascular diseases.
Figures
References
-
- Podgorski J, Berg M. Global threat of arsenic in groundwater. Science 2020;368(6493):845–850. - PubMed
-
- National Research Council. Critical aspects of EPA’s IRIS assessment of inorganic arsenic: Interim report. National Academies Press; 2013.
-
- Chen C-J, Chiou H-Y, Chiang M-H, Lin L-J, Tai T-Y. Dose-Response Relationship Between Ischemic Heart Disease Mortality and Long-term Arsenic Exposure. Arteriosclerosis, Thrombosis, and Vascular Biology 1996;16(4):504–510. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- HHSN268201600032C/ES/NIEHS NIH HHS/United States
- 75N92020D00001/HL/NHLBI NIH HHS/United States
- N01 HC095167/HL/NHLBI NIH HHS/United States
- R01 HL109284/HL/NHLBI NIH HHS/United States
- U01 HL065521/HL/NHLBI NIH HHS/United States
- R01 HL109282/HL/NHLBI NIH HHS/United States
- 75N92020D00002/HL/NHLBI NIH HHS/United States
- HHSN268201500003C/HL/NHLBI NIH HHS/United States
- N01 HC095161/HL/NHLBI NIH HHS/United States
- 75N92020D00005/HL/NHLBI NIH HHS/United States
- U01 HL041642/HL/NHLBI NIH HHS/United States
- N01 HC095168/HL/NHLBI NIH HHS/United States
- R01 HL120393/HL/NHLBI NIH HHS/United States
- U54 HG003067/HG/NHGRI NIH HHS/United States
- U01 HL041654/HL/NHLBI NIH HHS/United States
- HHSN268201600002C/HL/NHLBI NIH HHS/United States
- HHSN268201500001C/HL/NHLBI NIH HHS/United States
- UL1 TR001079/TR/NCATS NIH HHS/United States
- N02 HL064278/HL/NHLBI NIH HHS/United States
- N01 HC095169/HL/NHLBI NIH HHS/United States
- HHSN268201600018C/HL/NHLBI NIH HHS/United States
- U01 HL120393/HL/NHLBI NIH HHS/United States
- R01 ES025216/ES/NIEHS NIH HHS/United States
- P42 ES033719/ES/NIEHS NIH HHS/United States
- R01 HL090863/HL/NHLBI NIH HHS/United States
- U01 HL041652/HL/NHLBI NIH HHS/United States
- 75N92019D00029/HL/NHLBI NIH HHS/United States
- N01 HC095159/HL/NHLBI NIH HHS/United States
- 75N92020D00003/HL/NHLBI NIH HHS/United States
- R01 HL105756/HL/NHLBI NIH HHS/United States
- P42 ES010349/ES/NIEHS NIH HHS/United States
- P30 DK063491/DK/NIDDK NIH HHS/United States
- R01 HL146860/HL/NHLBI NIH HHS/United States
- R01 HL109315/HL/NHLBI NIH HHS/United States
- N01 HC025195/HL/NHLBI NIH HHS/United States
- 75N92019D00030/HL/NHLBI NIH HHS/United States
- HHSN268201600003C/HL/NHLBI NIH HHS/United States
- 75N92019D00028/HL/NHLBI NIH HHS/United States
- HHSN268201600038C/HL/NHLBI NIH HHS/United States
- HHSN268201500001I/HL/NHLBI NIH HHS/United States
- UL1 TR001420/TR/NCATS NIH HHS/United States
- 75N92020D00004/HL/NHLBI NIH HHS/United States
- HHSN268201600004C/HL/NHLBI NIH HHS/United States
- R01 HL109319/HL/NHLBI NIH HHS/United States
- N01 HC095163/HL/NHLBI NIH HHS/United States
- 75N92020D00007/HL/NHLBI NIH HHS/United States
- HHSN268201500003I/HL/NHLBI NIH HHS/United States
- HHSN268201600001C/HL/NHLBI NIH HHS/United States
- 75N92019D00031/HL/NHLBI NIH HHS/United States
- UL1 TR000040/TR/NCATS NIH HHS/United States
- N01 HC095166/HL/NHLBI NIH HHS/United States
- R01 HL151855/HL/NHLBI NIH HHS/United States
- 75N92019D00027/HL/NHLBI NIH HHS/United States
- 75N92020D00006/HL/NHLBI NIH HHS/United States
- R01 HL117626/HL/NHLBI NIH HHS/United States
- N01 HC095162/HL/NHLBI NIH HHS/United States
- UL1 TR001881/TR/NCATS NIH HHS/United States
- N01 HC095165/HL/NHLBI NIH HHS/United States
- N01 HC095164/HL/NHLBI NIH HHS/United States
- R01 HL109301/HL/NHLBI NIH HHS/United States
- U01 HL065520/HL/NHLBI NIH HHS/United States
- R01 ES021367/ES/NIEHS NIH HHS/United States
- P30 ES009089/ES/NIEHS NIH HHS/United States
- N01 HC095160/HL/NHLBI NIH HHS/United States
